BioNTech SE
BNTX
$107.34
-$0.16-0.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.51% | -27.67% | -52.12% | -69.09% | -76.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.51% | -27.67% | -52.12% | -69.09% | -76.63% |
| Cost of Revenue | -0.26% | -9.92% | -19.55% | -59.44% | -67.24% |
| Gross Profit | 0.71% | -30.99% | -55.47% | -70.54% | -78.25% |
| SG&A Expenses | 2.72% | 7.41% | 12.40% | 15.04% | 5.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 243.64% | 238.50% | 174.70% | -955.38% | -317.52% |
| Total Operating Expenses | 49.77% | 63.20% | 34.95% | -1.95% | -32.81% |
| Operating Income | -2,339.61% | -196.36% | -111.61% | -107.37% | -99.27% |
| Income Before Tax | -650.71% | -157.56% | -108.92% | -104.42% | -98.29% |
| Income Tax Expenses | -181.54% | -105.44% | -83.24% | -82.16% | -98.63% |
| Earnings from Continuing Operations | -786.05% | -171.78% | -117.67% | -112.20% | -98.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -786.05% | -171.78% | -117.67% | -112.20% | -98.16% |
| EBIT | -2,339.61% | -196.36% | -111.61% | -107.37% | -99.27% |
| EBITDA | -598.51% | -170.23% | -106.99% | -104.34% | -97.42% |
| EPS Basic | -772.17% | -172.03% | -117.83% | -112.22% | -98.11% |
| Normalized Basic EPS | -451.17% | -146.86% | -106.13% | -103.27% | -97.71% |
| EPS Diluted | -810.16% | -173.18% | -118.28% | -112.77% | -98.13% |
| Normalized Diluted EPS | -466.27% | -147.62% | -106.39% | -103.52% | -97.71% |
| Average Basic Shares Outstanding | 0.17% | -0.03% | -0.41% | -0.66% | -0.88% |
| Average Diluted Shares Outstanding | -0.03% | -0.47% | -0.91% | -2.28% | -3.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |